NCT00201747View on ClinicalTrials.gov

Sequentially Administered CPT-11 and Mitomycin C in Patients With Advanced Esophageal and Stomach Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

September 30, 2001

Primary Completion Date

October 31, 2006

Study Completion Date

February 28, 2010

Conditions
Esophageal CancerEsophagus CancerCancer of StomachStomach Cancer
Interventions
DRUG

CPT-11

CPT-11 will be administered intravenously on days 2 and 9 (24 hours after MMC, when the MMC is required) Two weeks of rest (beginning days 15 and 22) (drug free) will complete the cycle, with therapy planned to be resumed on day 29.

DRUG

Mitomycin C

MMC will be administered intravenously on day 1 (Arm A) and days 1 and 8 (Arm B)

Trial Locations (1)

43210

Ohio State University, Columbus

All Listed Sponsors
collaborator

Pharmacia and Upjohn

INDUSTRY

lead

Ohio State University Comprehensive Cancer Center

OTHER

NCT00201747 - Sequentially Administered CPT-11 and Mitomycin C in Patients With Advanced Esophageal and Stomach Cancer | Biotech Hunter | Biotech Hunter